Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006

被引:29
作者
Rastam, Samer [1 ,2 ]
Ali, Radwan A. L. [1 ]
Maziak, Wasim [1 ,3 ]
Mzayek, Fawaz [1 ,4 ]
Fouad, Fouad M. [1 ]
O'Flaherty, Martin [5 ]
Capewell, Simon [5 ]
机构
[1] Syrian Ctr Tobacco Studies, Aleppo, Syria
[2] Syrian Soc Against Canc Bldg, Syrian Ctr Tobacco Studies, St Aleppo, Shihan, Syria
[3] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Miami, FL 33199 USA
[4] Univ Memphis, Sch Publ Hlth, Div Epidemiol & Biostat, Memphis, TN 38152 USA
[5] Univ Liverpool, Dept Publ Hlth & Policy, Liverpool L69 3BX, Merseyside, England
基金
英国医学研究理事会;
关键词
Coronary heart disease; Mortality; Modelling; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; LATE REPERFUSION; ARTERY-DISEASE; STATIN THERAPY; METAANALYSIS; HEALTH; ASPIRIN; CLOPIDOGREL; FAILURE;
D O I
10.1186/1471-2458-12-754
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Despite advances made in treating coronary heart disease (CHD), mortality due to CHD in Syria has been increasing for the past two decades. This study aims to assess CHD mortality trends in Syria between 1996 and 2006 and to investigate the main factors associated with them. Methods: The IMPACT model was used to analyze CHD mortality trends in Syria based on numbers of CHD patients, utilization of specific treatments, trends in major cardiovascular risk factors in apparently healthy persons and CHD patients. Data sources for the IMPACT model included official statistics, published and unpublished surveys, data from neighboring countries, expert opinions, and randomized trials and meta-analyses. Results: Between 1996 and 2006, CHD mortality rate in Syria increased by 64%, which translates into 6370 excess CHD deaths in 2006 as compared to the number expected had the 1996 baseline rate held constant. Using the IMPACT model, it was estimated that increases in cardiovascular risk factors could explain approximately 5140 (81%) of the CHD deaths, while some 2145 deaths were prevented or postponed by medical and surgical treatments for CHD. Conclusion: Most of the recent increase in CHD mortality in Syria is attributable to increases in major cardiovascular risk factors. Treatments for CHD were able to prevent about a quarter of excess CHD deaths, despite suboptimal implementation. These findings stress the importance of population-based primary prevention strategies targeting major risk factors for CHD, as well as policies aimed at improving access and adherence to modern treatments of CHD.
引用
收藏
页数:9
相关论文
共 62 条
  • [1] Modifiable cardiovascular risk factors among adults in Aleppo, Syria
    Al Ali, Radwan
    Rastam, Samer
    Fouad, Fouad M.
    Mzayek, Fawaz
    Maziak, Wasim
    [J]. INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2011, 56 (06) : 653 - 662
  • [2] Anglotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function - A systematic review and meta-analysis of randomized controlled trials
    Al-Mallah, MH
    Tleyjeh, IM
    Abdel-Latif, AA
    Weaver, WD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1576 - 1583
  • [3] Epidemiology of Type 2 diabetes mellitus in Aleppo, Syria
    Albache, Nizar
    Al Ali, Radwan
    Rastam, Samer
    Fouad, Fouad M.
    Mzayek, Fawaz
    Maziak, Wasim
    [J]. JOURNAL OF DIABETES, 2010, 2 (02) : 85 - 91
  • [4] Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
    Anand, SS
    Yusuf, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2058 - 2067
  • [5] [Anonymous], 1998, Circulation, V97, P2202
  • [6] [Anonymous], 1988, LANCET, V2, P349
  • [7] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [8] NCDs: celebrating success, moving forward
    Beaglehole, Robert
    Bonita, Ruth
    Alleyne, George
    Horton, Richard
    [J]. LANCET, 2011, 378 (9799) : 1283 - 1284
  • [9] Optimal medical therapy with or without PCI for stable coronary disease
    Boden, William E.
    O'Rourke, Robert A.
    Teo, Koon K.
    Hartigan, Pamela M.
    Maron, David J.
    Kostuk, William J.
    Knudtson, Merril
    Dada, Marcin
    Casperson, Paul
    Harris, Crystal L.
    Chaitman, Bernard R.
    Shaw, Leslee
    Gosselin, Gilbert
    Nawaz, Shah
    Title, Lawrence M.
    Gau, Gerald
    Blaustein, Alvin S.
    Booth, David C.
    Bates, Eric R.
    Spertus, John A.
    Berman, Daniel S.
    Mancini, G. B. John
    Weintraub, William S.
    Boden, W.
    O'Rourke, R.
    Teo, K.
    Hartigan, P.
    Weintraub, W.
    Maron, D.
    Mancini, J.
    Weintraub, W.
    Boden, W.
    O'Rourke, R.
    Teo, K.
    Hartigan, P.
    Knudtson, M.
    Maron, D.
    Bates, E.
    Blaustein, A.
    Booth, D.
    Carere, R.
    Ellis, S.
    Gosselin, G.
    Gau, G.
    Jacobs, A.
    King, S., III
    Kostuk, W.
    Harris, C.
    Spertus, J.
    Peduzzi, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) : 1503 - 1516
  • [10] Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials
    Boersma, E
    Harrington, RA
    Moliterno, DJ
    White, H
    Théroux, P
    Van de Werf, F
    de Torbal, A
    Armstrong, PW
    Wallentin, LC
    Wilcox, RG
    Simes, J
    Califf, RM
    Topol, EJ
    Simoons, ML
    [J]. LANCET, 2002, 359 (9302) : 189 - 198